Related Experiment Video
Updated: Jul 3, 2026
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
[Effect of the raloxifene versus combined hormonal therapy on the mammary density]
Benigno Linares-Segovia1, José Antonio Rodríguez-Osorio, Germán Storms-Salas
1Facultad de Medicina de León, Universidad de Guanajuato, Unidad de Investigación en Epidemiología Clínica, IMSS, Guanajuato. blinares@salud.gob.mx
Objective:
to compare in postmenopausal women with osteoporosis or osteopenia the effect of hydrochlorate of raloxifene versus hormone replacement therapy on the mammary density.
Method:
a double blind, randomized clinical trial was conducted in 57 postmenopausal women older than 55 years with osteoporosis or osteopenia. Participants were randomly allocated in two groups: the intervention group (IG) received hydrochlorate of raloxifene and the control group (CG) received hormone replacement therapy during 6 months. A mammography to evaluate the change of the mammary density, according to the BIRADS criteria, was made before and after the treatment.
Results:
twenty-eight patients received hormone replacement therapy and 29 hydrochlorate of raloxifene. Eight (28.5 %) patients of the IG and one (3.0 %) of the CG showed an increased mammary density; whereas in none of IG patients and in four (13.7%) of the CG, the mammary density decreased (p = 0.01).
Conclusions:
the hydrochlorate of raloxifene in postmenopausal women with osteoporosis or osteopenia does not increase the mammary density.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022